ImmunoSolv merges to avoid 'one trick pony' syndrome

Edinburgh, Scotland-based ImmunoSolv is merging with Aberdeen's Grampian BioConsultants, combining the two companies' technical know-how to further explore the biology of cell death. ImmunoSolv also announced that it has raised £500,000 from Grampian BioPartners, the Scottish Enterprise Scottish Co-Investment Fund and the University of Edinburgh.

The new company will operate under the ImmunoSolv name, combining a complementary "portfolio of immunology and immuno-technology expertise." The funding will be used to grow the combined business, recruit a business development manager, and provide more R&D opportunities. The company hopes to have its first products in the clinic by 2012.

"...[T]he addition of GBC will ensure the company has the infrastructure, reach and product offerings to meet the needs of lab- based scientists, bio-manufacturers and clinicians in the fields of therapeutic cells and proteins worldwide," says ImmunoSolv CEO Ruth Murray.

- take a look at the Business7 report

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.